News
Shares of Mustang Bio ( NASDAQ: MBIO) jumped on Monday after the company said that the U.S. FDA has granted orphan drug ...
The safety update for Vyvgart rattled argenx’s shares on Monday, a reaction that analysts at William Blair said was “overdone ...
Two senior officials at the FDA's drug promotion regulatory office have resigned, leading to speculation that a clampdown on some direct-to-consumer (DTC) advertising of medicines could be on the way.
The FDA is moving at breakneck speed to roll out a generative artificial intelligence (AI) tool for speeding up regulatory reviews, announcing its launch nearly a month ahead of the 30th June ...
The Prescription Drug User Fee Act typically calls for a period of 10 months for the FDA to review such applications, although drugs that are deemed a priority have a review period of six months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results